Abstract
Purpose The aim of study is to determine the relationship between the inflammation and the severity of hypertension with the inflammation biomarkers; CRP, IL-1, proBNP, leptin, PTX-3 levels in children with obesity-related hypertension.
Material and Methods In our study, thirty patients (20 girls, 10 boys) who were admitted to İnönü University Turgut Özal Tıp Merkezi Department of Pediatrics between 2021-2022; between the ages of 2-17 and who were followed up in Pediatric Endocrinology, Pediatric Nephrology and Pediatric Cardiology clinics for obesity-related hypertension and 30 healthy children (22 girls, 8 boys) in the same age group were included. Clinical and demographic characteristics of all children; Age, gender, anthropometric measurements, blood pressure, 24-hour ambulatory blood pressure measurements echocardiographic findings were recorded. Left ventricular systolic and diastolic diameters, volumes and wall thickness measured by echocardiography and proportioned to body surface area. After the echocardiographic evaluation, a total of 10 cc blood was drawn from the individuals and patients in the control group and IL-1, CRP, Leptin, Pro-BNP, PTX-3 levels were measured. Statistical analysis was performed using SPSS (Statistical Program in Social Sciences) 22.0 software program
Results Systolic blood pressure, diastolic blood pressure, height, weight, body mass index were statistically significantly higher in the patient group. On echocardiographic evaluation, interventricular diastolic diameter (IVSd), left ventricular diastolic diameter (LVIDd), left ventricular posterior wall diastolic (LVPWd), interventricular systolic diameter (IVSs), left ventricular systolic diameter (LVIDs) and left ventricular diastolic diameter (LVIDd), left ventricular posterior wall systolic diameter (LVPWs) were statistically significantly higher in the patient group. LVs mass values, systolic blood pressure, diastolic blood pressure, height, weight, body mass index, IVSd, LVIDd, LVPWd, IVSs, LVIDs, LVPWs, LVs massvalues were statistically significantly higher in the patient group. In our study, when the inflammation variables in the patient and control groups were compared, leptin and CRP levels were found significantly higher in the obesity group (p:0,041). We found that there was a moderate positive correlation between leptin and systolic blood pressure in healthy children, moderately strong correlations between Pro-BNP and systolic blood pressure in the negative corelation, and a weak positive correlation between leptin and diastolic blood pressure in obesity group. When the correlations between inflammation parameters and blood pressure findings were examined in our study, positive and moderate (p:0,019 r:0,425) correlation was found between leptin and systolic blood pressure in healthy children, while negative moderate (p:0,001 r:-0,566) correlation between Pro-BNP and systolic blood pressure and positive weak correlation between leptin and diastolic blood pressure (p:0,036 r:0,384) were found in obese and hypertensive children. Leptin, systolic blood pressure, diastolic blood pressure, height, weight and body mass index, IVSd, LVIDd, LVPWd, IVSs, LVIDs, LVPWs and LVs mass values were found to be statistically significantly high in obese patients who were required anti-hypertensive treatment.
Conclusion The importance of inflammatory markers in the early diagnosis of obesity-related hypertension may guide the development of new therapeutic strategies to treat target organ damage by reducing the morbidity and mortality that can be caused by hypertension. . We think that the high levels of inlammation markers in obese patients may be a guide in the severity of hypertension, in the prevention of organ damage secondary to hypertension, in reversing inflammation and hypertension with more stringent lifestyle changes, diet and exercise.
However, prospective studies which compare pre- and post-treatment inflammation in children are needed to evaluate the effects of inflammation and its effects on prognosis.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The author(s) received no specific funding for this work.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Before study ethical permission was obtained from İnönü University Faculty of Medicine Health Sciences Clinical Research Ethics Committee and consent was obtained the individuals/parents who participated in the study.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All relevant data are within the manuscript and its Supporting Information files.
